Nambrol Bambini (Flunisolide)

Flunisolide, the active ingredient in Nambrol Bambini, is a corticosteroid presented as an inhalation for inhalation use. It treats asthma and allergic rhinitis in patients who need anti‑inflammatory control of the airways.

GNH USA supplies Nambrol Bambini as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Flunisolide is an inhaled glucocorticoid that acts on airway inflammation and allergic nasal mucosa. - Asthma: reduces airway inflammation, improves symptom control and decreases frequency of exacerbations. - Allergic rhinitis: decreases nasal inflammation, relieving congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: provides preventive anti‑inflammatory protection before physical activity.

Flunisolide may cause a range of adverse reactions, most of which are related to local airway exposure.

Common Side Effects: - Throat irritation or soreness. - Hoarseness or voice changes. - Cough or wheezing after inhalation. - Oral candidiasis (thrush). - Headache. - Nasal dryness or irritation.

Serious or Rare Side Effects: - Adrenal suppression with systemic effects. - Glaucoma or cataract formation with prolonged use. - Severe allergic reactions, including anaphylaxis. - Pneumonia or opportunistic infections. - Paradoxical bronchospasm immediately after inhalation.

When prescribing or using Flunisolide inhalation, consider the following safety measures. - Infection risk: monitor for signs of respiratory infection and treat promptly. - Growth monitoring: assess growth velocity in pediatric patients during long‑term therapy. - Spacer use: recommend a spacer device to reduce oropharyngeal deposition. - Discontinuation: avoid abrupt cessation after prolonged high‑dose use; taper as advised. - Oral hygiene: rinse mouth and gargle after each inhalation to prevent candidiasis. - Store at ambient temperature: keep in original packaging, protect from moisture and direct heat.

Flunisolide can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure. - Systemic corticosteroids: additive risk of adrenal suppression. - Live vaccines: immunosuppression may reduce vaccine effectiveness.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., fluconazole): may modestly raise flunisolide levels. - Diuretics: monitor electrolytes as glucocorticoids can affect potassium balance. - Beta‑agonists: possible reduced bronchodilator response; adjust therapy if needed.